


VAAST™ Platform Is a Powerful Product Development Engine

Completed 15 clinical trials against 7 different viruses, vaccinating 500+ subjects



1. Bivalent Phase 1 demonstrated IgA ASC response rates of 90 – 93% for GII.4 and 78 – 86% for GI.1
 2. Monovalent H1 flu vaccine completed phase 2 Proof of Concept efficacy study.
 3. Janssen collaboration with an option to negotiate an exclusive license.

4. RSV program to be partnered with new antigen partner.
 5. HPV therapeutic pre-IND feedback received.